Literature DB >> 526874

Does prior dantrolene affect the in vitro diagnosis of malignant hyperthermia susceptibility?

T E Nelson, E H Flewellen.   

Abstract

A therapeutic and prophylactic dose of dantrolene administered to malignant hyperthermia-susceptible pigs had no effect on the abnormal in vitro contracture response of subsequent muscle biopsies. The in vitro contracture response of MHS pig muscle to halothane and to caffeine was not altered by prior dantrolene treatment. It is concluded that prior dantrolene administration has no effect on the discrimination of porcine MSH by in vitro pharmacological testing.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 526874     DOI： 10.1007/BF03006162

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN： 0008-2856


  10 in total

1.  Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium.

Authors:  G G Harrison
Journal:  Br J Anaesth       Date:  1975-01       Impact factor: 9.166

2.  A new screening test for susceptibility to malignant hyperpyrexia.

Authors:  F R Ellis; D G Harriman
Journal:  Br J Anaesth       Date:  1973-06       Impact factor: 9.166

3.  Screening for malignant hyperpyrexia.

Authors:  T E Nelson; K L Austin; M A Denborough
Journal:  Br J Anaesth       Date:  1977-02       Impact factor: 9.166

4.  Metabolic error of muscle metabolism after recovery from malignant hyperthermia.

Authors:  W Kalow; B A Britt; M E Terreau; C Haist
Journal:  Lancet       Date:  1970-10-31       Impact factor: 79.321

5.  Treatment of porcine malignant hyperpyrexia. The successful use of dantrolene in the Pietrain pig.

Authors:  G M Hall; J N Lucke; D Lister
Journal:  Anaesthesia       Date:  1977-05       Impact factor: 6.955

6.  Porcine malignant hyperthermia: effect of dantrolene sodium on in-vitro halothane-induced contraction of susceptible muscle.

Authors:  I L Anderson; E W Jones
Journal:  Anesthesiology       Date:  1976-01       Impact factor: 7.892

7.  Porcine malignant hyperthermia: effects of temperature and extracellular calcium concentration on halothane-induced contracture of susceptible skeletal muscle.

Authors:  T E Nelson; D M Bedell; E W Jones
Journal:  Anesthesiology       Date:  1975-03       Impact factor: 7.892

8.  Biochemical basis of malignant hyperpyrexia.

Authors:  R F Moulds; M A Denborough
Journal:  Br Med J       Date:  1974-05-04

9.  Dantrolene in porcine malignant hyperthermia.

Authors:  G A Gronert; J H Milde; R A Theye
Journal:  Anesthesiology       Date:  1976-06       Impact factor: 7.892

10.  Rationale for dantrolene vs. procainamide for treatment of malignant hyperthermia.

Authors:  T E Nelson; E H Flewellen
Journal:  Anesthesiology       Date:  1979-02       Impact factor: 7.892
  10 in total
  5 in total

Review 1.  Dantrolene.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1984-01

2.  Is bacterial contamination of anaesthetic equipment adequately controlled by pasteurization alone?

Authors:  H Nielsen; J B Jacobsen; C Ringsted
Journal:  Can Anaesth Soc J       Date:  1980-05

3.  Dantrolene--in vitro studies in malignant hyperthermia susceptible (MHS) and normal skeletal muscle.

Authors:  B A Britt; E Scott; W Frodis; M J Clements; L Endrenyi
Journal:  Can Anaesth Soc J       Date:  1984-03

Review 4.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

5.  Fura-2 detected myoplasmic calcium and its correlation with contracture force in skeletal muscle from normal and malignant hyperthermia susceptible pigs.

Authors:  P A Iaizzo; W Klein; F Lehmann-Horn
Journal:  Pflugers Arch       Date:  1988-06       Impact factor: 3.657
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.